

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Antipsoriatics - Topical

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:	
HPP Member Number:		Fax:	Phone:
Date of Birth:		Office Contact:	
Patient Primary Phone:		NPI:	PA PROMISe ID:
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Line of Business:		Specialty Pharmacy (if app	licable):
Drug Name:		Strength:	
Quantity:		Refills:	
Directions:			
Diagnosis Code:	Diagnosis:		
HPP's maximum approval time is 12 months but may be less depending on the drug.			

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Is the requested drug prescribed for the treatment of a diagnosis that is indicated in the Food and Drug Administration (FDA) approved package labeling OR a medically accepted indication?			
☐ Yes	□ No		
Q2. Is the requested drug age-appropriate for the patient acc recognized compendia, or peer-reviewed medical literature?	ording to FDA-approved package labeling, nationally		
☐ Yes	□ No		
Q3. Does the patient have a contraindication to the prescribed medication?			
☐ Yes	□ No		
Q4. For a topical AhR agonist (Vtama), a. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to a 4-week trial of a topical corticosteroid approved or medically accepted for the treatment of the beneficiary's diagnosis; -AND- b. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to an 8-week trial of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis			
☐ Yes	□ No		
Q5. For a topical PDE4 inhibitor (Zoryve). a. Does the patient have a history of therapeutic failure of or topical corticosteroid approved or medically accepted for the b. Does the patient have a history of therapeutic failure of or topical calcineurin inhibitor approved or medically accepted for	treatment of the beneficiary's diagnosis -AND- a contraindication or an intolerance to an 8-week trial of a		
☐ Yes	□ No		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antipsoriatics - Topical

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
Q6. Does the patient have a documented history of therapeutic failure, contraindication to, or intolerance of the preferred topical antipsoriatic agents?		
☐ Yes	□ No	
Q7. Additional Information:		

Prescriber Signature

Date

Updated for 2023

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document